ID   HEM4_HUMAN              Reviewed;         265 AA.
AC   P10746; B2RC13; D3DRF7; Q9H2T1;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   10-MAY-2017, entry version 168.
DE   RecName: Full=Uroporphyrinogen-III synthase;
DE            Short=UROIIIS;
DE            Short=UROS;
DE            EC=4.2.1.75;
DE   AltName: Full=Hydroxymethylbilane hydrolyase [cyclizing];
DE   AltName: Full=Uroporphyrinogen-III cosynthase;
GN   Name=UROS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=3174619; DOI=10.1073/pnas.85.19.7049;
RA   Tsai S.-F., Bishop D.F., Desnick R.J.;
RT   "Human uroporphyrinogen III synthase: molecular cloning, nucleotide
RT   sequence, and expression of a full-length cDNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7049-7053(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=11112350; DOI=10.1006/geno.2000.6373;
RA   Aizencang G., Solis C., Bishop D.F., Warner C., Desnick R.J.;
RT   "Human uroporphyrinogen-III synthase: genomic organization,
RT   alternative promoters, and erythroid-specific expression.";
RL   Genomics 70:223-231(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   REVIEW ON VARIANTS.
RX   PubMed=8829650;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<187::AID-HUMU1>3.0.CO;2-8;
RA   Xu W., Astrin K.H., Desnick R.J.;
RT   "Molecular basis of congenital erythropoietic porphyria: mutations in
RT   the human uroporphyrinogen III synthase gene.";
RL   Hum. Mutat. 7:187-192(1996).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS), CATALYTIC ACTIVITY, SUBUNIT,
RP   MUTAGENESIS OF SER-63; ARG-65; THR-103; GLU-127; TYR-168; SER-197;
RP   LYS-220; THR-227 AND THR-228, AND CHARACTERIZATION OF VARIANT CEP
RP   ALA-62.
RX   PubMed=11689424; DOI=10.1093/emboj/20.21.5832;
RA   Mathews M.A., Schubert H.L., Whitby F.G., Alexander K.J., Schadick K.,
RA   Bergonia H.A., Phillips J.D., Hill C.P.;
RT   "Crystal structure of human uroporphyrinogen III synthase.";
RL   EMBO J. 20:5832-5839(2001).
RN   [9]
RP   VARIANTS CEP LEU-53 AND ARG-73.
RX   PubMed=2331520;
RA   Deybach J.-C., de Verneuil H., Boulechfar S., Grandchamp B.,
RA   Nordmann Y.;
RT   "Point mutations in the uroporphyrinogen III synthase gene in
RT   congenital erythropoietic porphyria (Gunther's disease).";
RL   Blood 75:1763-1765(1990).
RN   [10]
RP   VARIANTS CEP PHE-4; ARG-73 AND MET-228.
RX   PubMed=1733834; DOI=10.1007/BF00197267;
RA   Boulechfar S., da Silva V., Deybach J.-C., Nordmann Y., Grandchamp B.,
RA   de Verneuil H.;
RT   "Heterogeneity of mutations in the uroporphyrinogen III synthase gene
RT   in congenital erythropoietic porphyria.";
RL   Hum. Genet. 88:320-324(1992).
RN   [11]
RP   VARIANTS CEP ALA-62; VAL-66; ARG-73 AND MET-228.
RX   PubMed=1737856; DOI=10.1172/JCI115637;
RA   Warner C.A., Yoo H.-W., Roberts A.G., Desnick R.J.;
RT   "Congenital erythropoietic porphyria: identification and expression of
RT   exonic mutations in the uroporphyrinogen III synthase gene.";
RL   J. Clin. Invest. 89:693-700(1992).
RN   [12]
RP   VARIANTS CEP CYS-19; PHE-82; ALA-99; VAL-104 AND SER-225.
RX   PubMed=7860775; DOI=10.1172/JCI117742;
RA   Xu W., Warner C.A., Desnick R.J.;
RT   "Congenital erythropoietic porphyria: identification and expression of
RT   10 mutations in the uroporphyrinogen III synthase gene.";
RL   J. Clin. Invest. 95:905-912(1995).
RN   [13]
RP   VARIANT CEP PRO-212.
RX   PubMed=8655129; DOI=10.1007/BF02281859;
RA   Tanigawa K., Bensidhoum M., Takamura N., Namba H., Yamashita S.,
RA   de Verneuil H., Ged C.;
RT   "A novel point mutation in congenital erythropoietic porphyria in two
RT   members of Japanese family.";
RL   Hum. Genet. 97:557-560(1996).
RN   [14]
RP   VARIANT CEP PHE-3, AND CHARACTERIZATION OF VARIANT CEP PHE-3.
RX   PubMed=9188670;
RX   DOI=10.1002/(SICI)1096-8628(19970613)70:3<299::AID-AJMG16>3.0.CO;2-G;
RA   Takamura N., Hombrados I., Tanigawa K., Namba H., Nagayama Y.,
RA   de Verneuil H., Yamashita S.;
RT   "Novel point mutation in the uroporphyrinogen III synthase gene causes
RT   congenital erythropoietic porphyria of a Japanese family.";
RL   Am. J. Med. Genet. 70:299-302(1997).
RN   [15]
RP   VARIANT CEP ARG-188.
RX   PubMed=9834209;
RA   Tezcan I., Xu W., Gurgey A., Tuncer M., Cetin M., Oener C., Yetgin S.,
RA   Ersoy F., Aizencang G., Astrin K.H., Desnick R.J.;
RT   "Congenital erythropoietic porphyria successfully treated by
RT   allogeneic bone marrow transplantation.";
RL   Blood 92:4053-4058(1998).
RN   [16]
RP   VARIANT CEP ARG-73.
RX   PubMed=9803266; DOI=10.1046/j.1469-1809.1998.6230225.x;
RA   Frank J., Wang X., Lam H.M., Aita V.M., Jugert F.K., Goerz G.,
RA   Merk H.F., Poh-Fitzpatrick M.B., Christiano A.M.;
RT   "C73R is a hotspot mutation in the uroporphyrinogen III synthase gene
RT   in congenital erythropoietic porphyria.";
RL   Ann. Hum. Genet. 62:225-230(1998).
RN   [17]
RP   VARIANT CEP THR-129, AND CHARACTERIZATION OF VARIANT CEP THR-129.
RX   PubMed=11121156; DOI=10.1046/j.1523-1747.2000.0202a.x;
RA   Rogounovitch T., Takamura N., Hombrados I., Morel C., Tanaka T.,
RA   Kameyoshi Y., Shimizu-Yoshida Y., de Verneuil H., Yamashita S.;
RT   "Congenital erythropoietic porphyria: a novel homozygous mutation in a
RT   Japanese patient.";
RL   J. Invest. Dermatol. 115:1156-1156(2000).
RN   [18]
RP   VARIANTS CEP THR-69; ARG-73; TRP-188; 210-GLU-LEU-211 DELINS
RP   HIS-ILE-GLN-SER-GLN-ALA-GLN-SER-GLN-ALA-GLN-ASP-ASN; SER-219 AND
RP   MET-228, AND CHARACTERIZATION OF VARIANTS CEP THR-69; TRP-188 AND
RP   SER-219.
RX   PubMed=12060141; DOI=10.1046/j.1365-2141.2002.03558.x;
RA   Shady A.A., Colby B.R., Cunha L.F., Astrin K.H., Bishop D.F.,
RA   Desnick R.J.;
RT   "Congenital erythropoietic porphyria: identification and expression of
RT   eight novel mutations in the uroporphyrinogen III synthase gene.";
RL   Br. J. Haematol. 117:980-987(2002).
RN   [19]
RP   VARIANT CEP PRO-47, AND CHARACTERIZATION OF VARIANT CEP PRO-47.
RX   PubMed=15304101; DOI=10.1111/j.0022-202X.2004.23401.x;
RA   Ged C., Megarbane H., Chouery E., Lalanne M., Megarbane A.,
RA   de Verneuil H.;
RT   "Congenital erythropoietic porphyria: report of a novel mutation with
RT   absence of clinical manifestations in a homozygous mutant sibling.";
RL   J. Invest. Dermatol. 123:589-591(2004).
RN   [20]
RP   VARIANT CEP GLN-248.
RX   PubMed=21653323; DOI=10.1182/blood-2011-03-342873;
RA   To-Figueras J., Ducamp S., Clayton J., Badenas C., Delaby C., Ged C.,
RA   Lyoumi S., Gouya L., de Verneuil H., Beaumont C., Ferreira G.C.,
RA   Deybach J.C., Herrero C., Puy H.;
RT   "ALAS2 acts as a modifier gene in patients with congenital
RT   erythropoietic porphyria.";
RL   Blood 118:1443-1451(2011).
RN   [21]
RP   VARIANT CEP PRO-237.
RX   PubMed=22350154; DOI=10.1007/s11033-012-1497-z;
RA   Moghbeli M., Maleknejad M., Arabi A., Abbaszadegan M.R.;
RT   "Mutational analysis of uroporphyrinogen III cosynthase gene in
RT   Iranian families with congenital erythropoietic porphyria.";
RL   Mol. Biol. Rep. 39:6731-6735(2012).
CC   -!- FUNCTION: Catalyzes cyclization of the linear tetrapyrrole,
CC       hydroxymethylbilane, to the macrocyclic uroporphyrinogen III, the
CC       branch point for the various sub-pathways leading to the wide
CC       diversity of porphyrins. Porphyrins act as cofactors for a
CC       multitude of enzymes that perform a variety of processes within
CC       the cell such as methionine synthesis (vitamin B12) or oxygen
CC       transport (heme).
CC   -!- CATALYTIC ACTIVITY: Hydroxymethylbilane = uroporphyrinogen III +
CC       H(2)O. {ECO:0000269|PubMed:11689424}.
CC   -!- PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-
CC       IX biosynthesis; coproporphyrinogen-III from 5-aminolevulinate:
CC       step 3/4.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:11689424}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:11112350}.
CC   -!- DISEASE: Congenital erythropoietic porphyria (CEP) [MIM:263700]:
CC       Porphyrias are inherited defects in the biosynthesis of heme,
CC       resulting in the accumulation and increased excretion of
CC       porphyrins or porphyrin precursors. They are classified as
CC       erythropoietic or hepatic, depending on whether the enzyme
CC       deficiency occurs in red blood cells or in the liver. The
CC       manifestations of CEP are heterogeneous, ranging from nonimmune
CC       hydrops fetalis due to severe hemolytic anemia in utero to milder,
CC       later onset forms, which have only skin lesions due to cutaneous
CC       photosensitivity in adult life. The deficiency in UROS activity
CC       results in the non-enzymatic conversion of hydroxymethylbilane
CC       (HMB) into the uroporphyrinogen-I isomer.
CC       {ECO:0000269|PubMed:11121156, ECO:0000269|PubMed:11689424,
CC       ECO:0000269|PubMed:12060141, ECO:0000269|PubMed:15304101,
CC       ECO:0000269|PubMed:1733834, ECO:0000269|PubMed:1737856,
CC       ECO:0000269|PubMed:21653323, ECO:0000269|PubMed:22350154,
CC       ECO:0000269|PubMed:2331520, ECO:0000269|PubMed:7860775,
CC       ECO:0000269|PubMed:8655129, ECO:0000269|PubMed:9188670,
CC       ECO:0000269|PubMed:9803266, ECO:0000269|PubMed:9834209}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=Severe congenital erythropoietic porphyria is
CC       associated with non-immune hydrops fetalis, a generalized edema of
CC       the fetus with fluid accumulation in the body cavities due to non-
CC       immune causes. Non-immune hydrops fetalis is not a diagnosis in
CC       itself but a symptom, a feature of many genetic disorders, and the
CC       end-stage of a wide variety of disorders.
CC   -!- SIMILARITY: Belongs to the uroporphyrinogen-III synthase family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Variant Ala-62 was originally reported to result in no
CC       detectable enzyme activity (Ref.11), as measured in recombinant
CC       crude lysate extracts. Further experiments with the purified
CC       enzyme have shown that this variant does not affect activity
CC       (Ref.8). {ECO:0000269|PubMed:11689424,
CC       ECO:0000269|PubMed:1737856}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03824; AAA60273.1; -; mRNA.
DR   EMBL; AF230665; AAG36795.1; -; mRNA.
DR   EMBL; AH010036; AAG36794.1; -; Genomic_DNA.
DR   EMBL; AK314896; BAG37410.1; -; mRNA.
DR   EMBL; AL360176; CAI12087.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49221.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49222.1; -; Genomic_DNA.
DR   EMBL; BC002573; AAH02573.1; -; mRNA.
DR   CCDS; CCDS7648.1; -.
DR   PIR; A40483; A40483.
DR   RefSeq; NP_000366.1; NM_000375.2.
DR   UniGene; Hs.501376; -.
DR   UniGene; Hs.684451; -.
DR   PDB; 1JR2; X-ray; 1.84 A; A/B=1-265.
DR   PDBsum; 1JR2; -.
DR   ProteinModelPortal; P10746; -.
DR   SMR; P10746; -.
DR   BioGrid; 113236; 11.
DR   IntAct; P10746; 2.
DR   MINT; MINT-2863993; -.
DR   STRING; 9606.ENSP00000357775; -.
DR   ChEMBL; CHEMBL4433; -.
DR   iPTMnet; P10746; -.
DR   PhosphoSitePlus; P10746; -.
DR   BioMuta; UROS; -.
DR   DMDM; 122849; -.
DR   EPD; P10746; -.
DR   MaxQB; P10746; -.
DR   PaxDb; P10746; -.
DR   PeptideAtlas; P10746; -.
DR   PRIDE; P10746; -.
DR   DNASU; 7390; -.
DR   Ensembl; ENST00000368786; ENSP00000357775; ENSG00000188690.
DR   Ensembl; ENST00000368797; ENSP00000357787; ENSG00000188690.
DR   GeneID; 7390; -.
DR   KEGG; hsa:7390; -.
DR   UCSC; uc001liw.5; human.
DR   CTD; 7390; -.
DR   DisGeNET; 7390; -.
DR   GeneCards; UROS; -.
DR   GeneReviews; UROS; -.
DR   HGNC; HGNC:12592; UROS.
DR   HPA; HPA044038; -.
DR   MalaCards; UROS; -.
DR   MIM; 263700; phenotype.
DR   MIM; 606938; gene.
DR   neXtProt; NX_P10746; -.
DR   OpenTargets; ENSG00000188690; -.
DR   Orphanet; 79277; Congenital erythropoietic porphyria.
DR   PharmGKB; PA37222; -.
DR   eggNOG; KOG4132; Eukaryota.
DR   eggNOG; COG1587; LUCA.
DR   GeneTree; ENSGT00390000009853; -.
DR   HOGENOM; HOG000007209; -.
DR   HOVERGEN; HBG000492; -.
DR   InParanoid; P10746; -.
DR   KO; K01719; -.
DR   OMA; ALQPHGC; -.
DR   OrthoDB; EOG091G0F70; -.
DR   PhylomeDB; P10746; -.
DR   TreeFam; TF324092; -.
DR   BioCyc; MetaCyc:HS07569-MONOMER; -.
DR   BRENDA; 4.2.1.75; 2681.
DR   Reactome; R-HSA-189451; Heme biosynthesis.
DR   UniPathway; UPA00251; UER00320.
DR   EvolutionaryTrace; P10746; -.
DR   GenomeRNAi; 7390; -.
DR   PRO; PR:P10746; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000188690; -.
DR   CleanEx; HS_UROS; -.
DR   ExpressionAtlas; P10746; baseline and differential.
DR   Genevisible; P10746; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0048037; F:cofactor binding; IEA:Ensembl.
DR   GO; GO:0004852; F:uroporphyrinogen-III synthase activity; IDA:UniProtKB.
DR   GO; GO:0071418; P:cellular response to amine stimulus; IEA:Ensembl.
DR   GO; GO:0071243; P:cellular response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0006783; P:heme biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006782; P:protoporphyrinogen IX biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0006780; P:uroporphyrinogen III biosynthetic process; IDA:UniProtKB.
DR   CDD; cd06578; HemD; 1.
DR   InterPro; IPR003754; 4pyrrol_synth_uPrphyn_synth.
DR   Pfam; PF02602; HEM4; 1.
DR   SUPFAM; SSF69618; SSF69618; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Heme biosynthesis; Lyase; Polymorphism;
KW   Porphyrin biosynthesis; Reference proteome.
FT   CHAIN         1    265       Uroporphyrinogen-III synthase.
FT                                /FTId=PRO_0000135251.
FT   VARIANT       3      3       V -> F (in CEP; no residual activity;
FT                                dbSNP:rs773301339).
FT                                {ECO:0000269|PubMed:9188670}.
FT                                /FTId=VAR_021615.
FT   VARIANT       4      4       L -> F (in CEP; dbSNP:rs121908015).
FT                                {ECO:0000269|PubMed:1733834}.
FT                                /FTId=VAR_003674.
FT   VARIANT      19     19       Y -> C (in CEP).
FT                                {ECO:0000269|PubMed:7860775}.
FT                                /FTId=VAR_003675.
FT   VARIANT      47     47       S -> P (in CEP; severe cutaneous lesions;
FT                                less than 3% wild-type activity;
FT                                dbSNP:rs397515527).
FT                                {ECO:0000269|PubMed:15304101}.
FT                                /FTId=VAR_021616.
FT   VARIANT      53     53       P -> L (in CEP; severe phenotype; no
FT                                detectable activity; dbSNP:rs121908013).
FT                                {ECO:0000269|PubMed:2331520}.
FT                                /FTId=VAR_003676.
FT   VARIANT      62     62       T -> A (in CEP; does not affect enzymatic
FT                                activity; dbSNP:rs28941775).
FT                                {ECO:0000269|PubMed:11689424,
FT                                ECO:0000269|PubMed:1737856}.
FT                                /FTId=VAR_003677.
FT   VARIANT      66     66       A -> V (in CEP; mild phenotype; residual
FT                                activity; dbSNP:rs28941774).
FT                                {ECO:0000269|PubMed:1737856}.
FT                                /FTId=VAR_003678.
FT   VARIANT      69     69       A -> T (in CEP; less than 2% wild-type
FT                                activity). {ECO:0000269|PubMed:12060141}.
FT                                /FTId=VAR_021617.
FT   VARIANT      73     73       C -> R (in CEP; frequent mutation in
FT                                Western countries; severe phenotype; no
FT                                detectable activity; dbSNP:rs121908012).
FT                                {ECO:0000269|PubMed:12060141,
FT                                ECO:0000269|PubMed:1733834,
FT                                ECO:0000269|PubMed:1737856,
FT                                ECO:0000269|PubMed:2331520,
FT                                ECO:0000269|PubMed:9803266}.
FT                                /FTId=VAR_003679.
FT   VARIANT      82     82       V -> F (in CEP; mild phenotype; high
FT                                residual activity; dbSNP:rs121908016).
FT                                {ECO:0000269|PubMed:7860775}.
FT                                /FTId=VAR_003680.
FT   VARIANT      99     99       V -> A (in CEP).
FT                                {ECO:0000269|PubMed:7860775}.
FT                                /FTId=VAR_003681.
FT   VARIANT     104    104       A -> V (in CEP; residual activity;
FT                                dbSNP:rs397515528).
FT                                {ECO:0000269|PubMed:7860775}.
FT                                /FTId=VAR_003682.
FT   VARIANT     124    124       K -> R (in dbSNP:rs17153561).
FT                                /FTId=VAR_049345.
FT   VARIANT     129    129       I -> T (in CEP; no residual activity).
FT                                {ECO:0000269|PubMed:11121156}.
FT                                /FTId=VAR_021618.
FT   VARIANT     171    171       V -> G (in dbSNP:rs17173752).
FT                                /FTId=VAR_049346.
FT   VARIANT     188    188       G -> R (in CEP; less than 5% wild-type
FT                                activity; dbSNP:rs121908017).
FT                                {ECO:0000269|PubMed:9834209}.
FT                                /FTId=VAR_013558.
FT   VARIANT     188    188       G -> W (in CEP; mild phenotype; less than
FT                                2% wild-type activity;
FT                                dbSNP:rs121908017).
FT                                {ECO:0000269|PubMed:12060141}.
FT                                /FTId=VAR_021619.
FT   VARIANT     210    211       EL -> HIQSQAQSQAQDN (in CEP).
FT                                {ECO:0000269|PubMed:12060141}.
FT                                /FTId=VAR_021620.
FT   VARIANT     212    212       S -> P (in CEP; no residual activity;
FT                                dbSNP:rs139388833).
FT                                {ECO:0000269|PubMed:8655129}.
FT                                /FTId=VAR_003683.
FT   VARIANT     219    219       I -> S (in CEP; moderately-severe
FT                                phenotype; less than 2% wild-type
FT                                activity; dbSNP:rs767029901).
FT                                {ECO:0000269|PubMed:12060141}.
FT                                /FTId=VAR_021621.
FT   VARIANT     225    225       G -> S (in CEP; dbSNP:rs121908020).
FT                                {ECO:0000269|PubMed:7860775}.
FT                                /FTId=VAR_003684.
FT   VARIANT     228    228       T -> M (in CEP; no detectable activity;
FT                                dbSNP:rs121908014).
FT                                {ECO:0000269|PubMed:12060141,
FT                                ECO:0000269|PubMed:1733834,
FT                                ECO:0000269|PubMed:1737856}.
FT                                /FTId=VAR_003685.
FT   VARIANT     237    237       L -> P (in CEP; dbSNP:rs777433697).
FT                                {ECO:0000269|PubMed:22350154}.
FT                                /FTId=VAR_067318.
FT   VARIANT     248    248       P -> Q (in CEP; dbSNP:rs121908021).
FT                                {ECO:0000269|PubMed:21653323}.
FT                                /FTId=VAR_066247.
FT   MUTAGEN      63     63       S->A: Does not affect enzymatic activity.
FT                                {ECO:0000269|PubMed:11689424}.
FT   MUTAGEN      65     65       R->A: Slightly affects enzymatic
FT                                activity. {ECO:0000269|PubMed:11689424}.
FT   MUTAGEN     103    103       T->A: Slightly affects enzymatic
FT                                activity. {ECO:0000269|PubMed:11689424}.
FT   MUTAGEN     127    127       E->A: Does not affect enzymatic activity.
FT                                {ECO:0000269|PubMed:11689424}.
FT   MUTAGEN     168    168       Y->F: Impairs enzymatic activity.
FT                                {ECO:0000269|PubMed:11689424}.
FT   MUTAGEN     197    197       S->A: Does not affect enzymatic activity.
FT                                {ECO:0000269|PubMed:11689424}.
FT   MUTAGEN     220    220       K->A: Does not affect enzymatic activity.
FT                                {ECO:0000269|PubMed:11689424}.
FT   MUTAGEN     227    227       T->A: Does not affect enzymatic activity.
FT                                {ECO:0000269|PubMed:11689424}.
FT   MUTAGEN     228    228       T->A: Impairs enzymatic activity.
FT                                {ECO:0000269|PubMed:11689424}.
FT   STRAND        2      9       {ECO:0000244|PDB:1JR2}.
FT   HELIX        18     24       {ECO:0000244|PDB:1JR2}.
FT   TURN         25     27       {ECO:0000244|PDB:1JR2}.
FT   STRAND       29     34       {ECO:0000244|PDB:1JR2}.
FT   STRAND       36     40       {ECO:0000244|PDB:1JR2}.
FT   HELIX        43     50       {ECO:0000244|PDB:1JR2}.
FT   HELIX        53     55       {ECO:0000244|PDB:1JR2}.
FT   STRAND       57     61       {ECO:0000244|PDB:1JR2}.
FT   HELIX        64     76       {ECO:0000244|PDB:1JR2}.
FT   HELIX        80     86       {ECO:0000244|PDB:1JR2}.
FT   HELIX        88     93       {ECO:0000244|PDB:1JR2}.
FT   STRAND       94     98       {ECO:0000244|PDB:1JR2}.
FT   HELIX       101    109       {ECO:0000244|PDB:1JR2}.
FT   HELIX       122    130       {ECO:0000244|PDB:1JR2}.
FT   STRAND      139    144       {ECO:0000244|PDB:1JR2}.
FT   HELIX       146    148       {ECO:0000244|PDB:1JR2}.
FT   HELIX       151    156       {ECO:0000244|PDB:1JR2}.
FT   TURN        157    159       {ECO:0000244|PDB:1JR2}.
FT   STRAND      162    166       {ECO:0000244|PDB:1JR2}.
FT   STRAND      168    172       {ECO:0000244|PDB:1JR2}.
FT   HELIX       176    187       {ECO:0000244|PDB:1JR2}.
FT   STRAND      191    197       {ECO:0000244|PDB:1JR2}.
FT   HELIX       198    212       {ECO:0000244|PDB:1JR2}.
FT   HELIX       213    218       {ECO:0000244|PDB:1JR2}.
FT   STRAND      219    225       {ECO:0000244|PDB:1JR2}.
FT   HELIX       226    234       {ECO:0000244|PDB:1JR2}.
FT   STRAND      240    242       {ECO:0000244|PDB:1JR2}.
FT   STRAND      244    247       {ECO:0000244|PDB:1JR2}.
FT   HELIX       248    258       {ECO:0000244|PDB:1JR2}.
SQ   SEQUENCE   265 AA;  28628 MW;  CEF171401361F61E CRC64;
     MKVLLLKDAK EDDCGQDPYI RELGLYGLEA TLIPVLSFEF LSLPSFSEKL SHPEDYGGLI
     FTSPRAVEAA ELCLEQNNKT EVWERSLKEK WNAKSVYVVG NATASLVSKI GLDTEGETCG
     NAEKLAEYIC SRESSALPLL FPCGNLKREI LPKALKDKGI AMESITVYQT VAHPGIQGNL
     NSYYSQQGVP ASITFFSPSG LTYSLKHIQE LSGDNIDQIK FAAIGPTTAR ALAAQGLPVS
     CTAESPTPQA LATGIRKALQ PHGCC
//
